Iron Chelator in Patients with SickleCell Anemia, Comparative Study | ||
| kufa Journal for Nursing sciences | ||
| Article 1, Volume 4, Issue 3, December 2014, Pages 95-100 | ||
| Author | ||
| Talib Abduljaleel Jasim | ||
| Abstract | ||
| Background: the two main reasons for blood transfusion in sickle cell disease are to correct anemia so that the oxygen-carrying capacity of the blood is improved, and to treat or prevent painfulvasoocclusiveby lowering the proportion of sickle cell hemoglobin. Iron over load will be evitable. Aim: The aim of this study is to assessafety and efficiency of different chelation therapy. Patients and method:Fifty two patients divided in to two equalgroup, for treatment by combined Deferoxamine-Deferasirox therapy and on Deferasirox alone. Results: both drug regimens proved to have no adverse effect on hepatic or renal function. The degree of descend of serum ferritin is significantly higher with combined Deferoxamine-Deferasirox therapy. Conclusion: combined chelating agents have significant effect on serum ferritin, with acceptable level of safety. Recommendation: combined therapy was safe regime and can be used with good efficacy for patients with iron over load. | ||
| Keywords | ||
| sickle cell disease; Iron overload; Serum ferritin | ||
|
Statistics Article View: 195 PDF Download: 167 |
||